DCVC Bio

DCVC Bio is a venture capital firm that invests in early-stage life science companies leveraging deep-tech approaches. Founded in 2018, the firm focuses on therapeutics platforms, companies improving agriculture and food systems, and industrial biotechnologies. Their investment team comprises experts in genetics, chemistry, molecular biology, agriculture, industrial fermentation, and AI, combining scientific acumen with decades of operational management experience.

The firm's strategy centers on supporting foundational initiatives that utilize fundamental science and deep tech to solve complex problems. They are committed to using biology to create a more just, flourishing, and sustainable world. DCVC Bio seeks out and supports companies that can bring breakthrough medicines to the clinic or commercialize novel life sciences products.

DCVC Bio has made 60 investments, with notable exits including AbCellera, Chroma Medicine, and BioPhero. Their portfolio includes companies like Elo Life Systems, MycoWorks, and Sabanto, reflecting their diverse interests in biotechnology and life sciences. The firm closed its third fund, DCVC Bio III, at $400 million in October 2024, underscoring its commitment to advancing deep-tech innovations in the life sciences sector.